Biomarkers /
EGFR
Back to Biomarkers List
Overview
EGFR (epidermal growth factor receptor, also known as ERBB1 and HER1) is a gene that encodes for the epidermal growth factor receptor protein. Missense mutations, deletions, and insertions are observed in cancers such as lung cancer and glioblastoma. Activating EGFR mutations increase the kinase activity of EGFR, leading to hyperactivation of downstream pro-survival signaling pathways (PMID: 15284455).
EGFR is altered in 6.83% of all cancers with lung adenocarcinoma, conventional glioblastoma multiforme, glioblastoma, breast invasive ductal carcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in EGFR are EGFR Mutation (5.48%), EGFR Amplification (2.59%), EGFR Exon 19 Mutation (1.75%), EGFR Exon 19 Deletion (1.57%), and EGFR Exon 21 Mutation (1.28%) [3].
Biomarker-Directed Therapies
EGFR is a predictive biomarker for use of afatinib, osimertinib, erlotinib, gefitinib, dacomitinib, capmatinib, crizotinib, amivantamab, cetuximab, irinotecan, and pembrolizumab in patients.
Non-small cell lung carcinoma and colorectal carcinoma have the most therapies with EGFR as a predictive biomarker.
Of the therapies with EGFR as a predictive biomarker, 7 are FDA-approved in at least one clinical setting and 8 have NCCN guidelines in at least one clinical setting.
EGFR L858R, EGFR T790M, EGFR Exon 19 Deletion, EGFR E746_A750del, and EGFR C797S are the top alterations on EGFR targeted by therapies [4].
Afatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) | |
| Note: Single agent (FDA, NCCN), or may be considered in combination with cetuximab after progression on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy (NCCN). |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Single agent, or may be considered in combination with cetuximab after progression on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, SMC) |
Amivantamab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, with progression on or after platinum-based chemotherapy. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) | |
| Note: Single agent or in combination with ramucirumab (FDA, NCCN), or in combination with bevacizumab (NCCN, non-squamous only). |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Single agent, or in combination with bevacizumab (non-squamous only) or ramucirumab. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): First Line of Therapy (NICE, SMC), Metastatic (NICE, BNF, SMC) |
Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must not match any of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): First Line of Therapy (NICE), Metastatic (NICE, SMC) |
Irinotecan +
Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) | |
| Note: Indicated for metastatic, EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. Also NCCN-recommended as adjuvant therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Preferred first-line therapy, per NCCN. Also approved as adjuvant therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Preferred first-line therapy, per NCCN. Also recommended as adjuvant therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE, SMC) | |
| Note: Indicated for metastatic, EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement. |
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Cetuximab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, may be considered after progression on on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
EGFR status serves as an inclusion eligibility criteria in 353 clinical trials, of which 257 are open and 96 are closed. Of the trials that contain EGFR status as an inclusion criterion, 3 are early phase 1 (1 open), 88 are phase 1 (58 open), 53 are phase 1/phase 2 (37 open), 152 are phase 2 (115 open), 7 are phase 2/phase 3 (6 open), 38 are phase 3 (32 open), 5 are phase 4 (3 open), and 7 are no phase specified (5 open).
Trials with EGFR status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, non-squamous non-small cell lung carcinoma, malignant solid tumor, lung adenocarcinoma, and glioblastoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are EGFR L858R, EGFR Exon 19 Deletion, EGFR L861Q, EGFR S768I, and EGFR Exon 19 Insertion [4].
Osimertinib, pemetrexed, carboplatin, pembrolizumab, and placebo are the most frequent therapies in trials with EGFR as an inclusion criteria [4].
Significance of EGFR in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients [3].
EGFR is an inclusion criterion in 251 clinical trials for non-small cell lung carcinoma, of which 184 are open and 67 are closed. Of the trials that contain EGFR status and non-small cell lung carcinoma as inclusion criteria, 2 are early phase 1 (1 open), 58 are phase 1 (38 open), 37 are phase 1/phase 2 (28 open), 109 are phase 2 (82 open), 5 are phase 2/phase 3 (4 open), 29 are phase 3 (24 open), 4 are phase 4 (2 open), and 7 are no phase specified (5 open) [4].
Afatinib, osimertinib, gefitinib, erlotinib, dacomitinib, capmatinib, crizotinib, amivantamab, cetuximab, and pembrolizumab have evidence of efficacy in patients with EGFR mutation in non-small cell lung carcinoma [4].
Colorectal Carcinoma +
EGFR is altered in 3.22% of colorectal carcinoma patients [3].
EGFR is an inclusion criterion in 11 clinical trials for colorectal carcinoma, of which 8 are open and 3 are closed. Of the trials that contain EGFR status and colorectal carcinoma as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].
Irinotecan has evidence of efficacy in patients with EGFR mutation in colorectal carcinoma [4].
Malignant Solid Tumor +
EGFR is altered in 7.61% of malignant solid tumor patients [3].
EGFR is an inclusion criterion in 46 clinical trials for malignant solid tumor, of which 35 are open and 11 are closed. Of the trials that contain EGFR status and malignant solid tumor as inclusion criteria, 21 are phase 1 (15 open), 12 are phase 1/phase 2 (8 open), and 13 are phase 2 (12 open) [4].
Glioblastoma +
EGFR is altered in 31.54% of glioblastoma patients [3].
EGFR is an inclusion criterion in 26 clinical trials for glioblastoma, of which 17 are open and 9 are closed. Of the trials that contain EGFR status and glioblastoma as inclusion criteria, 11 are phase 1 (7 open), 4 are phase 1/phase 2 (3 open), 10 are phase 2 (6 open), and 1 is phase 2/phase 3 (1 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
EGFR is altered in 25.27% of non-squamous non-small cell lung carcinoma patients [3].
EGFR is an inclusion criterion in 15 clinical trials for non-squamous non-small cell lung carcinoma, of which 15 are open and 0 are closed. Of the trials that contain EGFR status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), 7 are phase 3 (7 open), and 1 is phase 4 (1 open) [4].
Breast Carcinoma +
EGFR is altered in 2.76% of breast carcinoma patients [3].
EGFR is an inclusion criterion in 14 clinical trials for breast carcinoma, of which 10 are open and 4 are closed. Of the trials that contain EGFR status and breast carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (0 open), and 7 are phase 2 (6 open) [4].
Lung Adenocarcinoma +
EGFR is altered in 26.09% of lung adenocarcinoma patients [3].
EGFR is an inclusion criterion in 12 clinical trials for lung adenocarcinoma, of which 9 are open and 3 are closed. Of the trials that contain EGFR status and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 2 are phase 3 (1 open) [4].
Gastric Carcinoma +
EGFR is altered in 5.88% of gastric carcinoma patients [3].
EGFR is an inclusion criterion in 9 clinical trials for gastric carcinoma, of which 6 are open and 3 are closed. Of the trials that contain EGFR status and gastric carcinoma as inclusion criteria, 3 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (3 open) [4].
Head And Neck Squamous Cell Carcinoma +
EGFR is altered in 6.43% of head and neck squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 6 are open and 1 is closed. Of the trials that contain EGFR status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Malignant Glioma +
EGFR is altered in 26.34% of malignant glioma patients [3].
EGFR is an inclusion criterion in 6 clinical trials for malignant glioma, of which 4 are open and 2 are closed. Of the trials that contain EGFR status and malignant glioma as inclusion criteria, 4 are phase 1 (4 open) and 2 are phase 1/phase 2 (0 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
EGFR is altered in 5.0% of adenocarcinoma of the gastroesophageal junction patients [3].
EGFR is an inclusion criterion in 6 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 2 are closed. Of the trials that contain EGFR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [4].
Urothelial Carcinoma +
EGFR is altered in 4.38% of urothelial carcinoma patients [3].
EGFR is an inclusion criterion in 6 clinical trials for urothelial carcinoma, of which 4 are open and 2 are closed. Of the trials that contain EGFR status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [4].
Squamous Cell Lung Carcinoma +
EGFR is altered in 6.88% of squamous cell lung carcinoma patients [3].
EGFR is an inclusion criterion in 5 clinical trials for squamous cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain EGFR status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].
Bladder Carcinoma +
EGFR is altered in 3.84% of bladder carcinoma patients [3].
EGFR is an inclusion criterion in 5 clinical trials for bladder carcinoma, of which 5 are open and 0 are closed. Of the trials that contain EGFR status and bladder carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 2 (3 open) [4].
Pancreatic Carcinoma +
EGFR is altered in 1.0% of pancreatic carcinoma patients [3].
EGFR is an inclusion criterion in 5 clinical trials for pancreatic carcinoma, of which 4 are open and 1 is closed. Of the trials that contain EGFR status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 2 (3 open) [4].
Small Cell Lung Carcinoma +
EGFR is altered in 9.38% of small cell lung carcinoma patients [3].
EGFR is an inclusion criterion in 4 clinical trials for small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].
Esophageal Carcinoma +
EGFR is altered in 8.33% of esophageal carcinoma patients [3].
EGFR is an inclusion criterion in 4 clinical trials for esophageal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain EGFR status and esophageal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Hepatocellular Carcinoma +
EGFR is altered in 1.84% of hepatocellular carcinoma patients [3].
EGFR is an inclusion criterion in 4 clinical trials for hepatocellular carcinoma, of which 3 are open and 1 is closed. Of the trials that contain EGFR status and hepatocellular carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Lung Carcinoma +
EGFR is altered in 22.35% of lung carcinoma patients [3].
EGFR is an inclusion criterion in 3 clinical trials for lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].
Glioma +
EGFR is altered in 19.88% of glioma patients [3].
EGFR is an inclusion criterion in 3 clinical trials for glioma, of which 1 is open and 2 are closed. Of the trials that contain EGFR status and glioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [4].
Anaplastic Astrocytoma +
EGFR is altered in 16.31% of anaplastic astrocytoma patients [3].
EGFR is an inclusion criterion in 3 clinical trials for anaplastic astrocytoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Gastric Adenocarcinoma +
EGFR is altered in 5.93% of gastric adenocarcinoma patients [3].
EGFR is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and gastric adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].
Head And Neck Carcinoma +
EGFR is altered in 4.29% of head and neck carcinoma patients [3].
EGFR is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Chordoma +
EGFR is an inclusion criterion in 3 clinical trials for chordoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and chordoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Malignant Central Nervous System Neoplasm +
EGFR is altered in 18.38% of malignant central nervous system neoplasm patients [3].
EGFR is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and malignant central nervous system neoplasm as inclusion criteria, 2 are phase 1 (2 open) [4].
Esophageal Squamous Cell Carcinoma +
EGFR is altered in 8.16% of esophageal squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for esophageal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and esophageal squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Anaplastic Oligoastrocytoma +
EGFR is altered in 6.25% of anaplastic oligoastrocytoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for anaplastic oligoastrocytoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Endometrial Carcinoma +
EGFR is altered in 4.71% of endometrial carcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Colorectal Adenocarcinoma +
EGFR is altered in 3.25% of colorectal adenocarcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Diffuse Intrinsic Pontine Glioma +
EGFR is altered in 1.96% of diffuse intrinsic pontine glioma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for diffuse intrinsic pontine glioma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Nasopharyngeal Carcinoma +
EGFR is altered in 1.37% of nasopharyngeal carcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for nasopharyngeal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Cholangiocarcinoma +
EGFR is altered in 2.41% of cholangiocarcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Cervical Carcinoma +
EGFR is altered in 1.28% of cervical carcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for cervical carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Medulloblastoma +
EGFR is altered in 1.09% of medulloblastoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for medulloblastoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Ovarian Carcinoma +
EGFR is altered in 1.36% of ovarian carcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Pancreatic Adenocarcinoma +
EGFR is altered in 1.02% of pancreatic adenocarcinoma patients [3].
EGFR is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].
Malignant Salivary Gland Neoplasm +
EGFR is altered in 0.98% of malignant salivary gland neoplasm patients [3].
EGFR is an inclusion criterion in 2 clinical trials for malignant salivary gland neoplasm, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and malignant salivary gland neoplasm as inclusion criteria, 2 are phase 2 (2 open) [4].
Hypopharyngeal Squamous Cell Carcinoma +
EGFR is altered in 9.52% of hypopharyngeal squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Laryngeal Squamous Cell Carcinoma +
EGFR is altered in 12.94% of laryngeal squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Laryngeal Neoplasm +
EGFR is altered in 12.94% of malignant laryngeal neoplasm patients [3].
EGFR is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Skin Squamous Cell Carcinoma +
EGFR is altered in 14.35% of skin squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for skin squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and skin squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Glioblastoma, IDH-Wildtype +
EGFR is altered in 14.71% of glioblastoma, IDH-wildtype patients [3].
EGFR is an inclusion criterion in 1 clinical trial for glioblastoma, IDH-wildtype, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and glioblastoma, IDH-wildtype as inclusion criteria, 1 is phase 2 (1 open) [4].
Lip And Oral Cavity Carcinoma +
EGFR is altered in 8.25% of lip and oral cavity carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Oral Cavity Squamous Cell Carcinoma +
EGFR is altered in 8.25% of oral cavity squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Lung Neuroendocrine Neoplasm +
EGFR is altered in 7.11% of lung neuroendocrine neoplasm patients [3].
EGFR is an inclusion criterion in 1 clinical trial for lung neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and lung neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Nasal Cavity And Paranasal Sinus Carcinoma +
EGFR is altered in 7.14% of nasal cavity and paranasal sinus carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Neuroendocrine Carcinoma +
EGFR is altered in 4.79% of neuroendocrine carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and neuroendocrine carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Peritoneal Carcinoma +
EGFR is altered in 4.35% of primary peritoneal carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Anaplastic Oligodendroglioma +
EGFR is altered in 3.89% of anaplastic oligodendroglioma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Uterine Neoplasm +
EGFR is altered in 3.53% of malignant uterine neoplasm patients [3].
EGFR is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Small Intestinal Carcinoma +
EGFR is altered in 3.73% of small intestinal carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR status and small intestinal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Oropharyngeal Squamous Cell Carcinoma +
EGFR is altered in 4.04% of oropharyngeal squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Diffuse Midline Glioma, H3 K27M-Mutant +
EGFR is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [3].
EGFR is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [4].
Cervical Squamous Cell Carcinoma +
EGFR is altered in 2.2% of cervical squamous cell carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Fallopian Tube Carcinoma +
EGFR is altered in 4.76% of fallopian tube carcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Hepatobiliary Neoplasm +
EGFR is altered in 2.5% of malignant hepatobiliary neoplasm patients [3].
EGFR is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
B-Cell Non-Hodgkin Lymphoma +
EGFR is altered in 1.63% of B-cell non-hodgkin lymphoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ovarian Epithelial Tumor +
EGFR is altered in 1.47% of ovarian epithelial tumor patients [3].
EGFR is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
EGFR is altered in 1.36% of high grade ovarian serous adenocarcinoma patients [3].
EGFR is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Primitive Neuroectodermal Tumor +
EGFR is altered in 1.18% of primitive neuroectodermal tumor patients [3].
EGFR is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 0 are open and 1 is closed. Of the trial that contains EGFR status and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Gastrointestinal Stromal Tumor +
EGFR is altered in 0.74% of gastrointestinal stromal tumor patients [3].
EGFR is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Anal Canal Squamous Cell Carcinoma +
EGFR is an inclusion criterion in 1 clinical trial for anal canal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Bronchogenic Carcinoma +
EGFR is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ependymoma +
EGFR is an inclusion criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR status and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Malignant Supratentorial Neoplasm +
EGFR is an inclusion criterion in 1 clinical trial for malignant supratentorial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and malignant supratentorial neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Pancreatic Ductal Adenocarcinoma +
EGFR is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pituitary Gland Carcinoma +
EGFR is an inclusion criterion in 1 clinical trial for pituitary gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and pituitary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +
EGFR is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ureter Carcinoma +
EGFR is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
